Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)‘s stock had its “buy” rating reiterated by Maxim Group in a research report issued to clients and investors on Wednesday, AnalystRatings.com reports. They currently have a $1.50 target price on the biotechnology company’s stock.
Separately, Zacks Investment Research raised shares of Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.25 price target for the company in a research note on Wednesday, November 20th.
NYSEAMERICAN:ATNM opened at $0.22 on Wednesday. Actinium Pharmaceuticals has a twelve month low of $0.19 and a twelve month high of $0.71.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.04) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04).
Several large investors have recently modified their holdings of the company. Oppenheimer & Co. Inc. raised its holdings in Actinium Pharmaceuticals by 34.6% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 236,281 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 60,769 shares during the last quarter. Sio Capital Management LLC lifted its position in Actinium Pharmaceuticals by 1,352.4% in the 2nd quarter. Sio Capital Management LLC now owns 4,935,250 shares of the biotechnology company’s stock valued at $1,214,000 after acquiring an additional 4,595,454 shares in the last quarter. Finally, Sabby Management LLC lifted its position in Actinium Pharmaceuticals by 5.4% in the 3rd quarter. Sabby Management LLC now owns 8,797,509 shares of the biotechnology company’s stock valued at $2,023,000 after acquiring an additional 453,793 shares in the last quarter.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.